Patients Undergoing Dental Surgery who are Taking Antiplatelet Medications by AL  AMRI, ALI ABDULLAH A et al.
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 
ISSN 2422-8419     An International Peer-reviewed Journal 
Vol.45, 2017 
 
92 
Patients Undergoing Dental Surgery who are Taking Antiplatelet 
Medications 
 
DR. ALI ABDULLAH A AL AMRI      Dr. Saleh Ali Alanazi 
Dr. Hussain Hamdan Ali Turi      Dr. Munif Odhayb Alruwaili 
 
Abstract 
For the undergoing dental surgery patients taking antiplatelet medications, physicians and dentists must weigh 
the bleeding risks in continuing antiplatelet medications versus the thrombotic risks in interrupting antiplatelet 
medications. Bleeding complications requiring more than local measures for hemostasis are rare after dental 
surgery in patients taking antiplatelet medications. Conversely, the risk for thrombotic complications after 
interruption of antiplatelet therapy for dental procedures apparently is significant, although small. When a 
clinician is faced with a decision to continue or interrupt antiplatelet therapy for a dental surgical patient, the 
decision comes down to “bleed or die.” That is, there is a remote chance that continuing antiplatelet therapy will 
result in a (nonfatal) bleeding problem requiring more than local measures for hemostasis versus a small but 
significant chance that interrupting antiplatelet therapy will result in a (possibly fatal) thromboembolic 
complication. The decision is simple: It is time to stop interrupting antiplatelet therapy for dental surgery. 
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1.1 Introduction 
More than 2000 years ago has witnessed the history of aspirin (acetylsalicylic acid), when Hippocrates 
recommended chewing on willow leaves (which contain salicylic acid) during childbirth for analgesia. In 1899, 
the chemist Felix Hoffman of Bayer AG (Leverkusen, Germany) was the first to isolate pure acetylsalicylic acid, 
later calling it “Aspirin” for commercial manufacture and sale. Since then, Bayer AG lost or sold its rights to the 
trademark, and the “wonder drug” aspirin is widely used for its analgesic, antipyretic, anti-inflammatory, and 
anti-thrombotic effects. Aspirin’s antithrombotic indications include atrial fibrillation, history of angina or 
myocardial infarction, coronary artery disease prevention, history of coronary bypass surgery, and percutaneous 
coronary intervention and stent implantation. 
Some of the newer agents are associated with greater antithrombotic efficacy but also higher bleeding risks 
than aspirin. When dental surgery is contemplated in patients taking 1 or more of these medications, dentists and 
physicians must weigh the potential bleeding risks in continuing the medications versus the thromboembolic 
risks in interrupting them before dental surgery (Ferrari, Benhamou, Cerboni & Marcel, 2005). Dentists 
frequently recommend aspirin withdrawal before dental surgery, even without consulting the patient’s physician. 
Both physicians and dentists frequently overestimate the bleeding risks of dental surgery in patients continuing 
antiplatelet medications and underestimate the thrombotic risks of interrupting antiplatelet therapy for dental 
procedures (Van Diermen, Waal & Hoogvliets, 2013). 
Dental surgery is unlike other types of surgery: Major vessels are unlikely to be encountered, and the 
perioperative and postoperative surgical sites are easily accessible to local measures for hemostasis, such as 
biting on gauze, absorbable gelatin sponges, and sutures. As early as 1987, Salzman stated, “The hemostatic 
defect induced by aspirin in patients with otherwise normal hemostasis is usually minor (Salzman, 1987). 
There have been many reports of patients continuing antiplatelet agents while undergoing dental surgery. Of 
at least 1283 patients taking single or dual antiplatelet agents undergoing at least 2343 dental surgical procedures, 
including at least 2308 single and multiple, simple, and surgical dental extractions in at least 1334 visits, no more 
than 35 patients (2.7% of patients and 2.6% of visits) had bleeding complications requiring local measures for 
hemostasis and only 2 patients (0.2%) required more than local measures for hemostasis. It should be noted that 
the risks of bleeding may differ on the basis of the antiplatelet agent and the regimen used. 
Although some of the newer agents and regimens may be associated with higher bleeding risks, none of the 
patients taking non-aspirin or dual antiplatelet agents had bleeding complications that required more than local 
hemostatic measures. 
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1.2 Literature Review 
In 1974, Lemkin et al reported on a patient taking 12 to 20 daily aspirin tablets (dosage unreported) who had 
uncontrolled bleeding after undergoing 18 extractions. The history included ethanol abuse, but the patient denied 
recent alcohol ingestion. Sutures and oxidized cellulose were unsuccessful 
for hemostasis, and the patient was admitted to the hospital the next day. Hemostasis was achieved after a 
platelet transfusion. Although the dose is unreported, 12 to 20 daily aspirin tablets were probably more than 
therapeutic and almost certainly more than the single daily tablet typically prescribed today for anti-thrombosis. 
In 1997, Thomason et al reported on a kidney transplant recipient who underwent a gingivectomy for 
gingival overgrowth and was taking aspirin 150 mg/day, in addition to cyclosporine, azathioprine, and 
amlodipine. Hemostasis was achieved with pressure from gauze after the lower anterior gingivectomy, but after 
the upper anterior gingivectomy, there was excessive hemorrhage uncontrolled with local measures, and the 
patient was admitted to the hospital for a platelet transfusion, after which hemostasis was achieved. It is not clear 
that the relatively low dose of aspirin was the cause of the postoperative bleeding. 
Although the evidence shows that dental surgery can be accomplished with minimal bleeding risk in 
patients receiving single or dual antiplatelet medications, some have recommended a 7- to 10-day interruption of 
antiplatelet therapy for dental extractions (Ogle & Hernandez, 1998). There are various levels of thrombotic risk 
associated with continuous antiplatelet therapy interruption, depending on the reason for the antithrombotic 
therapy. For example, there is a relatively low risk of thrombotic complications when single antiplatelet therapy 
is withdrawn in primary prevention patients versus a relatively high risk when dual antiplatelet therapy is 
withdrawn in patients after recent percutaneous coronary intervention. Whenever antiplatelet therapy is 
interrupted, regardless of the reason, there is at least some increased risk of thrombotic complications. In a case-
control study of Biondi-Zoccai et al, 513 patients who had a first-ever prescription of low dose aspirin over a 7-
year period, García Rodríguez et al determined that patients who had recently interrupted aspirin were 
significantly more likely to have a myocardial infarction than patients whose aspirin therapy was continued. “For 
every 1000 patients, over a period of one year there were about four more cases of non-fatal myocardial 
infarction among patients who discontinued treatment with low dose aspirin (recent discontinuers) compared 
with patients who continued treatment.” Garcia Rodríguez et al also showed a 40% increased risk of ischemic 
stroke or transient ischemic attack after withdrawal of aspirin within 1 to 3 months in patients with 
cardiovascular disease or cerebrovascular disease. 
Biondi-Zoccai et al conducted a meta-analysis of 50,279 patients in 6 studies and concluded that aspirin 
nonadherence or withdrawal was associated with a 3 times higher risk of a major adverse cardiac event versus 
continuing aspirin therapy. The authors concluded that the withdrawal of aspirin can have an “ominous 
prognostic implication” in patients at moderate or high risk for coronary artery disease. Sibon and Orgogozo 
studied 289 patients with cerebral infarction and found that 13 of these patients had had antiplatelet drug 
interruption within 1 month before the ischemic stroke. Maulaz et al conducted a case-control study of 309 
patients admitted for stroke or transient ischemic attack who had been on aspirin therapy versus 309 controls on 
aspirin with history of stroke but no stroke or transient ischemic attack within 6 months. There were 13 patients 
who had discontinued aspirin in the 4 weeks before the ischemic event, of whom 7 had been instructed to 
withdraw aspirin by a physician for a surgical procedure or because the physician thought aspirin was not 
necessary. The authors concluded that preoperative withdrawal of aspirin therapy “may not always be the best 
solution” before surgical procedures. 
 
1.3 Data discussion 
Although most studies of antiplatelet medication interruption for dental procedures have shown no thrombotic 
complications (Table 1), there have been some cases of thrombotic complications when antiplatelet medications 
were interrupted for dental procedures (Table 1). 
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Table 1: Antiplatelet Withdrawal for Dental Procedures 
Source No. of 
Patients 
Treated 
No. of 
Cessations 
No. of 
Extractions 
Antiplatelet 
Medications 
Comment Days of 
Withdrawal 
Thrombotic Complications 
Ardekian 
et al 2000 
20 34 34 Aspirin  7 0 
Candemir 
et al 2010 
1 1 1 Clopidogrel Warfarin 
was 
continued 
10 1 myocardial infarction due 
to very late stent thrombosis 
Kovacic 
et al 2012 
197 197 197 Aspirin, 
clopidogrel, 
aspirin and 
clopidogrel 
 Not 
reported 
Less than 2 cases of stent 
thrombosis or acute 
myocardial infarction 
Loomba 
et al 2012 
1 1 1 Aspirin  3 0 
Candemir et al reported a case of a 50-year-old man with chest pain, who had been on warfarin and 
clopidogrel but decided on his own to withdraw clopidogrel 10 days before a dental procedure. He was 
diagnosed with late stent thrombosis and myocardial infarction. Collet et al retrospectively analyzed 475 
consecutive patients with myocardial infarction, 11 of whom had interrupted aspirin therapy within 15 days 
before hospital admission. One of these patients discontinued aspirin 8 days before dental surgery and had a 
myocardial infarction 2 days later. 
Ferrari et al studied 1236 patients with acute coronary syndrome, 51 of whom were hospitalized within 1 
month of aspirin withdrawal. In 13 cases, dental treatment was the reason for the aspirin withdrawal. Kovacic et 
al studied a group of 5681 patients receiving dual antiplatelet therapy with aspirin and clopidogrel after drug-
eluting stent implantation. Of 1611 patients who had 1 or both antiplatelet agents interrupted over a 5-year 
period, 17 had stent thrombosis or acute myocardial infarction after the interruption. There were 197 patients 
whose antiplatelet therapy was interrupted for dental procedures, at least 2 of whom had stent thrombosis or 
acute myocardial infarction after the interruption (J. Kovacic, personal communication, March 23, 2013). 
The authors concluded that rates of stent thrombosis or acute myocardial infarction are low but not 
insignificant after drug-eluting stent implantation. At least 17 of 324 patients (5%) whose antiplatelet 
medications were interrupted for dental surgery had thrombotic complications. The actual overall risk of 
antiplatelet cessation is probably significantly less than 5%, but more than zero. In the study by Kovacic et al, 
the rate of thrombotic complications in patients whose antiplatelet medications were interrupted for any reason 
(not just dental procedures) was approximately 1% of all cessations, and even this number seems high. Patients 
receiving dual antiplatelet therapy after drug-eluting stent implantation are at higher risk than many other 
patients receiving antiplatelet therapy, so it is difficult to extrapolate these results to other patients receiving 
antiplatelet therapy, but because the risk of hemorrhage after dental surgery in patients receiving antiplatelet 
medications is extraordinarily low, antiplatelet medication interruption for dental procedures exposes patients to 
an unnecessarily increased risk (although still low) of serious thrombotic complications. 
 
1.4 National Medical and Dental Group Recommendations for Dental Surgery in Patients Taking 
Antiplatelet Medications and Recommendations of Other Reviews 
The American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and 
Interventions, American College of Surgeons, and American Dental Association have stated that single or dual 
antiplatelet therapy should not be interrupted for dental procedures, concluding, “Given the relative ease with 
which the incidence and severity of oral bleeding can be reduced with local measures during surgery (eg, 
absorbable gelatin sponge and sutures) and the unlikely occurrence of bleeding once an initial clot has formed, 
there is little or no indication to interrupt antiplatelet drugs for dental procedures.” The American College of 
Chest Physicians also recommends continuing aspirin for dental surgery. In reviewing the literature in 2007, 
Brennan et al concluded that dental extractions can be performed with minimal bleeding risk in patients on 
continuous low-dose aspirin. In “extenuating” circumstances, when antiplatelet therapy should be interrupted, 
then the interruption should be for no more than 3 days to minimize the risk of thrombosis. 
Napeñas et al conducted a literature review of bleeding complications in dental patients taking antiplatelet 
agents in 2013, focusing on 15 studies, which showed there is not a significantly increased risk of postoperative 
bleeding complications in patients receiving single or dual antiplatelet therapy, although there may be increased 
bleeding risk in patients receiving combination antiplatelet and anticoagulant therapy. The authors concluded 
there is no need to stop single or dual antiplatelet therapy for invasive dental procedures, and local measures are 
adequate for hemostasis. 
van Diermen et al searched the literature and expert recommendations from 2007 to 2012 and concluded 
that antithrombotic medications including dual antiplatelet therapy should not be interrupted for simple dental 
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procedures, including extractions. 
 
1.5 Conclusions 
When a clinician is faced with a decision to continue or interrupt antiplatelet therapy for a dental surgical patient, 
the decision comes down to “bleed or die.” That is, there is a remote (w0.2%) chance that continuing antiplatelet 
therapy will result in a (nonfatal) bleeding problem requiring more than local measures for hemostasis versus an 
unknown but significant chance that interrupting antiplatelet therapy will result in a (possibly fatal) 
thromboembolic complication. 
The decision is fairly simple: It is time to stop interrupting antiplatelet therapy for dental surgery 
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